Abstract
Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.
| Original language | English |
|---|---|
| Pages (from-to) | 1493-1498 |
| Number of pages | 6 |
| Journal | Journal of Orthopaedic Research |
| Volume | 30 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2012 Sep |
Fingerprint
Keywords
- molecular targeted therapy
- pazopanib
- PI3K-AKT pathway
- synovial sarcoma
ASJC Scopus subject areas
- Orthopedics and Sports Medicine
Cite this
A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. / Hosaka, Seiichi; Horiuchi, Keisuke; Yoda, Masaki; Nakayama, Turrent Robert; Tohmonda, Takahide; Susa, Michiro; Nakamura, Masaya; Chiba, Kazuhiro; Toyama, Yoshiaki; Morioka, Hideo.
In: Journal of Orthopaedic Research, Vol. 30, No. 9, 09.2012, p. 1493-1498.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway
AU - Hosaka, Seiichi
AU - Horiuchi, Keisuke
AU - Yoda, Masaki
AU - Nakayama, Turrent Robert
AU - Tohmonda, Takahide
AU - Susa, Michiro
AU - Nakamura, Masaya
AU - Chiba, Kazuhiro
AU - Toyama, Yoshiaki
AU - Morioka, Hideo
PY - 2012/9
Y1 - 2012/9
N2 - Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.
AB - Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.
KW - molecular targeted therapy
KW - pazopanib
KW - PI3K-AKT pathway
KW - synovial sarcoma
UR - http://www.scopus.com/inward/record.url?scp=84863836492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863836492&partnerID=8YFLogxK
U2 - 10.1002/jor.22091
DO - 10.1002/jor.22091
M3 - Article
VL - 30
SP - 1493
EP - 1498
JO - Journal of Orthopaedic Research
JF - Journal of Orthopaedic Research
SN - 0736-0266
IS - 9
ER -